American Society of Hirudotherapy

Informed Consent Forms

Template and checklist for hirudotherapy informed consent

Last Updated: March 5, 2026Reviewed by: Andrei Dokukin, MD

Last updated: March 14, 2026

Legal Requirement

Written informed consent is mandatory before initiating leech therapy. Failure to obtain adequate informed consent is the highest-risk scenario for malpractice liability. The consent obligation is heightened by three factors: (a) the procedure involves a living organism that produces intentional wounds; (b) there is a well-documented risk of serious bacterial infection; and (c) most clinical uses are off-label.

Required Disclosures

Nature of Procedure

  • Application of live, FDA-cleared medicinal leeches (510(k)-cleared medical device)
  • Each leech creates a Y-shaped bite wound and feeds for 20-45 minutes
  • Prolonged bleeding (typically 4–24 hours, occasionally longer in anticoagulated patients) is an expected therapeutic effect, not a complication

Common Side Effects

  • Localized itching at bite site (37-75% of patients)
  • Regional lymphadenitis (6-13% of patients)
  • Mild-to-moderate blood loss per session
  • Residual Y-shaped scar at each bite site (~2-3 mm)
  • Mild stinging at bite initiation (resolves in 1-2 min)

Serious Risks

Aeromonas Infection

7-20% of treatment courses without prophylaxis, <5% with prophylaxis. Aeromonas hydrophila and related species are obligate symbionts of the leech gut. Infection may manifest up to 26 days after treatment. One documented case of lethal sepsis (A. veronii). Aeromonas meningitis has been reported. Cases of fluoroquinolone-resistant infection have been published.

Other Serious Risks

  • Blood loss requiring transfusion: 49.75% of microsurgical patients require transfusion (Whitaker et al., 2012)
  • Allergic reaction: Rare; ranges from localized urticaria to anaphylaxis
  • Treatment failure: ~78% flap salvage rate; 22% may require resection despite therapy. Infection reduces salvage to 37.4%

Off-Label Disclosure

Mandatory for Non-Surgical Uses

For any use beyond the FDA-cleared indications (venous congestion in grafts, flaps, and replanted tissues), the consent form must explicitly state:

  • The proposed use is off-label
  • The FDA has not evaluated safety or effectiveness for the specific condition
  • Available evidence may be limited
  • The patient understands and accepts the off-label nature of the treatment

Antibiotic Prophylaxis Disclosure

Standard of Care Requirement

The consent process must inform the patient that prophylactic antibiotic therapy is part of the standard of care. Patient refusal of prophylactic antibiotics is grounds for withholding leech therapy (Mumcuoglu et al., 2014). This must be documented as a condition of treatment.

Alternatives Section

Treatment Alternatives to Disclose

  • Heparin-soaked gauze/pledgets (chemical leeching)
  • Surgical revision of venous anastomosis
  • Hyperbaric oxygen therapy
  • Negative pressure wound therapy
  • Observation and conservative management

Related Resources

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.